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Bacillus Calmette–Guérin (BCG), the only licensed vaccine against tuberculosis, has 
been shown to provide heterologous protection against unrelated pathogens and 
enhance antibody responses to several routine expanded program on immunization 
(EPI) vaccines. Understanding these heterologous effects is important for the develop-
ment of optimal vaccination strategies. We set out to assess the effect of vaccination 
with BCG Russia of 6-week-old infants on in vitro reactivity to a panel of toll-like receptor 
(TLR) agonists (TLR2, 4, and 7/8) and heat-killed pathogens [Streptococcus pneumo-
niae, Candida albicans (CA), and Escherichia coli], and antibody responses to other EPI 
vaccines compared to BCG naïve infants. We observed no effect of BCG vaccination 
on innate (TNF-α) or Th2 (IL-4) cytokine responses, but found enhanced CA-specific 
CD8+IFN-γ+ responses in BCG vaccinated males and females 1 week after vaccina-
tion and decreased IFN-γ:IL4 ratio to SP in females. By 12 weeks (but not 1 week) 
of post-vaccination, there was significant downmodulation of Th1 cytokine responses 
in BCG vaccinated infants; and TLR-stimulated IL-10 and IL-17 responses declined 
in BCG vaccinated females but not males. Significant changes also occurred in the 
BCG naïve group, mainly at 18 weeks, including decreased Th1 and increased IL-10 
responses. The effects at 18 weeks were most likely a result of immune modulation by 
the intervening EPI vaccines given at 8, 12, and 16 weeks of age. There was no effect of 
BCG vaccination on EPI antibody levels at either time point. Taken together, our results 
support minimal early heterologous immune modulation by BCG Russia vaccination that 
did not persist 12 weeks after vaccination.
Keywords: vaccine, toll-like receptors, non-specific effects, heterologous effects, cytokines, innate immunity, 
adaptive immunity
TaBle 1 | Vaccines given throughout the study.
Bcg group control group
Birth OPV, HepB OPV, HepB
6 weeks Bcg Nil
8 weeks Penta 1 (Hib, HepB, 
DTwP), PCV-13, OPV
Penta 1 (Hib, HepB, DTwP), PCV-13, OPV
12 weeks Penta 2 (Hib, HepB, 
DTwP), PCV-13, OPV
Penta 2 (Hib, HepB, DTwP), PCV-13, OPV
16 weeks Penta 3 (Hib, HepB, 
DTwP), PCV-13, OPV
Penta 3 (Hib, HepB, DTwP), PCV-13, OPV
18 weeks TST TST then Bcg
All vaccines given to study infants from birth to the end of the study at  
18 weeks of age.
OPV, oral polio vaccine; HBV, hepatitis B vaccine; BCG, bacillus Calmette–Guérin 
vaccine; Penta, pentavalent vaccine; PCV-13, 13-valent pneumococcal conjugate 
vaccine; DTwP, diphtheria-tetanus-whole cell pertussis vaccine; Hib, Haemophilus 
influenzae group b vaccine; TST, tuberculin skin test.
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inTrODUcTiOn
Tuberculosis (TB) is a significant public health problem with 
approximately two billion people infected globally (1). Bacillus 
Calmette–Guérin (BCG) is the only licensed vaccine against TB, 
and while it provides good protection against disseminated TB in 
childhood, it has poor efficacy against adult pulmonary TB (2, 3). 
Several reasons have been given for the variability in efficacy 
throughout the world, including, but not limited to, different 
strains of BCG vaccine (4–6), geographical location (7), and age 
at vaccination (8, 9).
Neonates have Th2-biased immunity and are thus susceptible 
to microbial infections requiring Th1 immunity for clearance, 
such as TB (10–12). Despite this, BCG vaccination at birth can 
induce a robust adaptive immune response, inducing poly-
functional Th1 cells (13–15) and Th17 cells (8, 16–18). Besides 
inducing a classical antigen-specific T  cell response, BCG 
vaccination also induces an innate immune response involving 
dendritic cell activation, natural killer (NK) and NK T  cells, 
and neutrophils (19–22). The innate immune system plays a 
critical protective role against infectious diseases throughout 
life, inducing a rapid immunological response against invading 
pathogens prior to the generation of adaptive immunity. This is 
particularly important in early life when adaptive immunity is 
poorly developed.
Toll-like receptors (TLRs) expressed by host immune cells rec-
ognize pathogen-associated molecular patterns (PAMPs), requi-
red for microbial recognition by macrophages and dendritic cells 
(23, 24). TLR ligands have been used in murine models as vaccine 
adjuvants, leading to enhanced Th1 responses (25). Certain TLR 
polymorphisms have been associated with an increase in BCG 
induced Th-1 type responses in whole blood 10  weeks after 
BCG vaccination in South African infants (26). Furthermore, 
BCG has been shown to induce epigenetic reprogramming of 
innate immune cells toward a pro-inflammatory profile charac-
terized by increased IFN-γ, TNF-α, and IL-1β in both murine 
models and adult European individuals (27). These studies showed 
that innate cells exhibit characteristics of adaptive immunity or 
adaptation to secondary infection in a process termed “trained 
immunity.” This immune training by BCG vaccination was 
further able to enhance innate immunity to other unrelated 
pathogens including Candida albicans (CA), Staphylococcus 
aureus, and Streptococcus pneumoniae (SP) (27).
Epidemiological studies dating back to the 1940s have sug-
gested that BCG vaccination provides protection against unre-
lated infections, and vaccination is associated with a decrease in 
all-cause mortality in certain settings (28). A meta-analysis of 
clinical trial data from the US and UK in the 1940s and 1950s 
estimated a 25% reduction from diseases other than TB when 
BCG was given (29). Randomized controlled trials in Guinea 
Bissau have shown that BCG vaccination of low birth weight 
neonates is associated with an almost 50% reduction in all-cause 
mortality in the first few weeks of life, mainly from unrelated 
infections (30). In an analysis of almost half a million child-
hood hospitalization episodes in the official Spanish registry, 
BCG vaccination was associated with a 32.4–66.6% reduction 
in hospitalization due to respiratory infection, and a 52% 
reduction in sepsis in <1-year olds (31). Similarly, data from 
two large cohorts of children (n = 58,021 and 93,301) from 19 
countries found a 17–37% reduction in acute lower respiratory 
tract infection in BCG vaccinated children (32). Other evidence 
for non-specific effects of BCG include its widespread use as a 
therapeutic agent against bladder cancer (33) and as an adjunc-
tive therapy for malignant melanoma (34). BCG has also been 
shown to boost antibody responses to other expanded program 
on immunization (EPI) vaccines supporting an adjuvant effect 
in humans (15, 35).
Interestingly, non-specific effects of vaccines have been 
shown to manifest differently in the sexes, with females generally 
being more susceptible than males to the non-specific effects of 
vaccination (36–38). Indeed, the protection against death in the 
low birth weight studies occurred in the first 3  days of life in 
males and after 1 week in females, suggesting different mecha-
nisms (30). Despite these important findings, the underlying 
immunological mechanisms are still not understood.
Herein, we conducted a randomized trial aimed at assessing 
the effect of BCG vaccination of 6-week-old Gambian infants on 
in vitro responses to toll-like receptor (TLR) ligands, unrelated 
pathogens, and antibody responses to EPI vaccines compared to 
a BCG naïve control group. Our results support early enhanced 
CA-specific IFN-γ responses in BCG vaccinated infants but no 
effect on TNF-α or EPI vaccine antibody responses. Our find-
ings contribute to the relatively scarce evidence for heterologous 
immunological effects of BCG vaccination in humans.
MaTerials anD MeThODs
study site and subject recruitment
Expectant mothers, presenting at the Sukuta Health Centre 
(a  peri-urban setting in The Gambia) for antenatal care were 
sensitized about the study. Their children were recruited into the 
study upon birth or when they presented for BCG vaccination 
(within 48 h of birth). BCG vaccination was withheld for those 
that agreed to participate (Table 1). Exclusion criteria included 
low birth weight (<2.5 kg), congenital defects, and multiple births.
FigUre 1 | Participant numbers and drop outs. Numbers of study infants throughout the study from recruitment at birth, to enrollment and randomization, and 
follow-up until 18 weeks of age. Infants were bled at three time points—Visit 1 (V1) at 6 weeks of age (baseline), visit 2 (V2) at 7 weeks (+1 week) and visit 3 (V3)  
at 18 weeks of age (+12 weeks).
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ethics statement
The Scientific Coordinating Committee (SCC) at the Medical 
Research Council (MRC) Unit, The Gambia and the MRC-
Gambian Government Joint Ethics Committee approved this 
study (study number SCC 1233). Written informed consent 
was provided by the parent/guardian of participating infants in 
accordance with the Declaration of Helsinki.
Blood sampling and Vaccination
Infants were randomized at 6 weeks of age into one of two groups: 
0.1  mL intradermal vaccination with BCG vaccine (Russian 
strain, SSI India) (BCG group) or no vaccination (Control group) 
to be given at 6 weeks of age. All infants received hepatitis B vac-
cine (HepB) (Serum Institute of India) and oral polio vaccine 
(OPV) (Sanofi Pasteur, France) at birth in accordance with the 
EPI schedule of The Gambia. At 8, 12, and 16 weeks, all infants 
received the pentavalent [diphtheria–tetanus–whole cell pertus-
sis, Haemophilus influenzae B (Hib), HepB] vaccine (Panacea 
biotech, India), OPV, and the 13-valent pneumococcal conjugate 
vaccine (PCV-13) (Table 1). At 18 weeks of age, all infants were 
tested by standard tuberculin skin test (TST) for mycobacte-
rial reactivity by injecting 0.1 mL containing 2 U of tuberculin 
(Serum Staten Institut, Denmark) intradermally. Induration was 
read longitudinally and transversely by a trained nurse at 48–72 h 
to determine the average induration. The infants in the BCG 
naïve control group were then vaccinated with BCG at 18 weeks 
of age. A maximum of 5 mL of venous whole blood was collected 
into EDTA tubes at 6 weeks (prior to BCG vaccination of group 
1) [Visit 1 (V1)], 7 weeks (1 week post-BCG vaccination) [Visit 
2 (V2)], and 18 weeks (12 weeks post-BCG vaccination) [Visit 3 
(V3)] (Figure 1).
Peripheral Blood Mononuclear cell 
(PBMc) separation and cryopreservation
EDTA blood was spun at 1,500  rpm for 10  min and 1  mL of 
plasma collected and stored at −20°C until use. The remaining 
whole blood was diluted 1:1 with RPMI (Sigma, UK) and PBMC 
separation was performed via density gradient centrifugation 
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on a Lymphoprep (Fresenius Kabi Norge AS, Norway) cush-
ion. Harvested PBMCs were washed twice in RPMI and cells 
counted using Trypan blue exclusion. For every 10 million live 
cells, 500 µL of fetal calf serum (FCS) (Gibco, Life technologies, 
USA) was added, cells were left on ice for 30 min and 500 μL of 
20% dimethyl sulfoxide (Sigma-Aldrich, UK) in FCS was added 
before cells were transferred into a Nalgene® Mr Frosty container 
(Sigma-Aldrich) and stored at −70°C then transferred to liquid 
nitrogen within 24 h.
PBMc Thawing
Peripheral Blood Mononuclear Cells were thawed rapidly at 
37°C in a water bath. Cells were then resuspended slowly in 
warm 10% FCS in RPMI (R10) prior to washing twice. Viability 
counts were done on the samples before being resuspended in 
R10 and 25 U/mL of benzonuclease (Sigma, UK). PBMCs were 
then rested at 37°C 5% CO2 for 6 h.
In Vitro culture conditions
0.1 × 106 PBMCs in 100 µL of culture medium (2% penicillin/
streptomycin, 1% l-glutamine, and 10% FCS in RPMI) were 
stimulated in 96-well round bottom plates for 16  h with the 
following antigens: purified protein derivative (PPD) (10  µg/
mL, Serum Staten Institute, Denmark), heat-killed Listeria 
monocytogenes (HKLM) (TLR2 agonist; 109/mL, Invivogen), 
lipopolysaccharide (LPS) (TLR4 ligand; 1  µg/mL, Invivogen), 
CLO-75 (TLR7/8 agonist; 10 µg/mL, Invivogen); and heat-killed 
Streptococcus pneumonia (SP) (105  cells/mL), CA (105  cells/
mL), or Escherichia coli (EC) (106  cells/mL). PMA/ionomycin 
(0.1 μg/1 μg/mL, Sigma, UK) was used as a positive control, and 
RPMI as a negative control. Supernatants were collected after 
the addition of 100 µL of RPMI and centrifugation at 1,500 rpm 
for 10 min. Supernatants were stored at −20°C until needed for 
cytokine analysis.
Multiplex cytokine assays
Cytokines in culture supernatants were assessed using Bioplex 
Pro custom made kits according to the manufacturer’s instruc-
tions using a 1:2 dilution of reagents (Bio-Rad, Belgium). The 
cytokines analyzed were IFN-γ, TNF-α, IL-2, IL-4, IL-10, IL-17, 
and IL-12(p70). Defrosted culture supernatants were centri-
fuged for 5  min to pellet any precipitate and left on ice until 
use. Coupled magnetic beads were diluted 1:2 with assay buffer, 
and added to pre-wet 96-well filter plates. Plates were washed 
using a vacuum manifold station. 50 µL of samples and standard 
were added and the plate incubated on a shaker at 300 rpm for 
30 min at room temperature. Detection antibodies were diluted 
1:2 with detection antibody diluents, 25 µL added to the plate 
after three washes, and incubated for 30  min on a shaker at 
room temperature. The plate was washed three times using the 
vacuum manifold before addition of 50 µL of streptavidin, and 
then incubated for 10 min on a shaker. 125 µL of assay buffer 
was added and plates left on a shaker until ready to be read using 
the Bioplex 200 system, Luminex x-map technology, and Bioplex 
pro software version 4.0 (Bio-Rad, Belgium).
All values less than the lowest value of the standard within the 
standard curve were given the value of the lowest standard and 
all values higher than the highest standard were given the value 
of the highest standard. The range in picograms per milliliter for 
each analyte is as follows: IL-2 (0.88–14,426), IL-4 (0.35–5,693), 
IL-10 (1.45–23,718), IL-12p70 (2.65–43,449), IL-17 (2.33–38,209), 
IFN-γ (2.05–33,560), and TNF-α (6.69–109,604). Background 
(unstimulated) values were subtracted from antigen-stimulated 
values to determine the antigen-specific response.
intracellular cytokine staining
0.5 ×  106 PBMCs were stimulated with RPMI, PMA/ionomy-
cin, PPD, a peptide pool of the TB-specific antigens ESAT-6/
CFP-10 (2.5 µg/mL, ProImmune, UK), heat-killed SP (105 cells/
mL), C. albicans (105 cells/mL), or E. coli (106 cells/mL) per test. 
Cells were incubated at 37°C 5% CO2 for 18 h with Brefeldin A 
(10 µg/mL) added after the first 2 h of incubation. Cells were 
stained with a live/dead aqua yellow stain (Invitrogen, USA), 
incubated for 10  min at room temperature before staining 
with a surface marker cocktail consisting of either CD3-PerCP 
Cy5.5 or CD3 APC efluor 750 and CD8 APC efluor 780. Cells 
were incubated for 30  min at room temperature and washed 
with 1 mL of PBS/1% FCS/0.2% Sodium Azide (FACS buffer). 
Supernatant was removed and cells washed in perm/wash solu-
tion (Ebioscience, UK). Permeabilization was then performed 
using fix/perm solution (Ebioscience) and cells incubated for 
20 min at 4°C before centrifugation at 1,800 rpm for 5 min. A 
cocktail of intracellular cytokines IL-2 FITC, IL-17 PE, TNF-α 
PE-Cy7, IL-10 efluor-450, and IFN-γ APC (all from ebioscience) 
was added, and cells incubated for 30 min at room temperature. 
Cells were washed with perm/wash solution and 300 µL FACS 
buffer was added before acquisition. At least 100,000 lympho-
cytes were acquired for each sample on a CyanADP (Beckman 
Coulter, USA) flow cytometer using Summit v4 software and 
analyzed using FlowJo v10.0.2 (Tree Star, USA) according to 
the gating strategy shown (Figures S1 and S2 in Supplementary 
Material).
Vaccine antibody assays
Stored plasma samples were used to measure antibody levels to 
polio 1 and 3 using the antibody neutralizing assay as described 
previously (39). Briefly, Hep-2 Cincinnati cells were cultured 
with different dilutions of the virus and subject plasma, cyto-
pathic effect of the virus on the plasma was assessed after 5 days 
incubation. Hepatitis B antibody levels were measured using a 
commercial ELISA kit (Diasorin, Italy) as per the manufacturer’s 
instructions. Diphtheria, tetanus, and pertussis antibodies were 
assessed in house using a multiplex immunoassay developed 
by the RIVM in the Netherlands as described previously (40), 
and antibody levels were measured using the Bioplex 200 system 
(Bio-Rad, Belgium).
statistical analysis
Cytokine multiplex, intracellular staining (ICS), and antibody 
data were analyzed by fitting a linear mixed model using restricted 
maximum likelihood. Bleed, vaccine group and sex, and their 
interactions were fitted as fixed effects, and infant and sample 
within infant, were fitted as random effects. The F-test was used 
to test for interactions between the fixed effects, in particular the 
TaBle 2 | Tuberculin skin test reactivity at 18 weeks of age.
number 
tested
number 
responders (%)
Median 
induration in mm 
(iQ range)
All naïve controls 52 7 (13.5) 0 (0, 0)
Naïve control females 26 4 (15.4) 0 (0, 0)
Naïve control males 26 3 (11.5) 0 (0, 0)
All bacillus Calmette–
Guérin (BCG) vaccinated
53 32 (60.4) 4.5 (0, 10.5)
BCG vaccinated females 24 12 (50) 1.25 (0, 5)
BCG vaccinated males 29 20 (69) 8.5 (0, 12.5)
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two-way group-by-bleed and three-way sex-by-group-by-bleed 
interactions. Comparisons between treatment groups, and sexes 
within treatment groups, at each time point, were based on t-tests 
utilizing the predicted means and SEs of differences recovered 
from the fitted mixed model. Comparisons were conducted at the 
5% significance level with no adjustments for multiplicity of out-
come variables or comparisons. Ratios of cytokines were intrinsi-
cally skewed and required logarithmic transformation prior to 
analysis, whereas diagnostic plots of residuals indicated that the 
cytokine data did not require log transformation. Logarithmic 
transformations were also required to overcome heterogeneity of 
variance in the antibody data. Data were analyzed using GenStat 
17 (VSN International), R 3.1.2 (www.r-project.org), and Stata 
version 12.1 (StataCorp LP, USA).
resUlTs
infant characteristics
137 infants were recruited into the study at birth with males 
and females randomized separately (Figure 1). The groups were 
of equivalent weight-for-age z scores at recruitment (data not 
shown). At 6 weeks (range 5–7 weeks), 131 babies remained in 
the study and were randomized to one of the two study groups: 
67 infants (34 males and 33 females) received BCG and 64 (35 
males and 29 females) were randomized to the control group and 
received BCG at 18 weeks upon study completion (Figure 1).
lack of enhanced In Vitro PPD reactivity, 
but greater TsT responses, in Bcg 
Vaccinated infants
Tuberculin skin test reactivity and in  vitro PPD assays were 
used to assess mycobacterial responses post-vaccination. The 
BCG vaccinated group had greater TST reactivity than the 
naïve control group (Table 2). Thus, while only 7 of 52 (13.5%) 
BCG naïve infants had a positive TST response (any indura-
tion > 1 mm), 32 of 53 (60.4%) BCG vaccinated infants were 
TST positive. The median induration in the unvaccinated infants 
was 0 (IQ range 0, 0) further indicating low level TST activity 
in this group, as compared to the BCG vaccinated group who 
had a median induration of 4.5 mm (IQ range 0, 10.5) (Control 
group vs BCG group p <  0.0001). The BCG vaccinated males 
had greater induration than females (M 8.5  mm, F 1.25  mm, 
M vs F p = 0.014) and responded more frequently than females 
(M = 69%, F = 50%).
Surprisingly, there was no evidence of a boosting of PPD 
reactivity in the BCG vaccinated group at V2 or V3 for any 
of the cytokines tested in culture supernatants (Table S1 in 
Supplementary Material). On the contrary, in BCG vaccinated 
females but not males the PPD-specific IL-12(p70) (p = 0.0025) 
(Figure 2A), IFN-γ (p = 0.0003) (Figure 2B), IL-4 (p = 0.0018) 
(Figure  2C), IL-10 (p  =  0.004) (Figure  2D), and IL-17 
(p =  0.0003) (Figure  2E) had all declined by V3 compared to 
V2. By contrast, the BCG naïve group had an increase in IFN-γ 
(p = 0.0164) (Figure 2A), IL-4 (p = 0.0018) (Figure 2C), IL-10 
(p = 0.004) (Figure 2D), and IL-17 (p = 0.0003) (Figure 2E) at 
V2 compared to baseline.
Intracellular staining by flow cytometry was performed to 
characterize CD4 and CD8 T cells, and innate cells (CD3− cells) 
expressing IL-2, IL-17, TNF-α, IL-10, IFN-γ, or combina-
tions of these cytokines intracellularly (Figures S1 and S2 in 
Supplementary Material). This failed to show any significant sex, 
group, or time interactions for PPD-specific CD4+, CD8+, or 
CD3− ICS responses for any of the cytokines in BCG vaccinated 
or control infants (data not shown).
no effects of Bcg Vaccination  
on innate cytokine responses
Levels of the innate pro-inflammatory cytokine TNF-α were 
analyzed in the TLR ligand and pathogen culture supernatants 
after overnight stimulation. While robust TNF-α responses were 
detected to the TLR ligands (Table S2 in Supplementary Material) 
and heat-killed pathogens (Table S3 in Supplementary Material), 
there was no difference in TNF-α responses between BCG vac-
cinated and naïve infants nor between males and females. In 
keeping with the soluble cytokine data, there was no effect of 
vaccine group, bleeding time point or sex on TNF-α responses by 
ICS of CD4+, CD8+, or CD3− cells (data not shown).
sex-Differential effects of Bcg 
Vaccination on Th1/Th2 Polarizing 
cytokines
IL-12(p70) (V1 vs V3 p = 0.0355) and IFN-γ (V1 vs V3 p = 0.0018; 
V2 vs V3 p = 0.0232) responses declined to the TLR4 ligand LPS 
in BCG vaccinated females, and IL-12(p70) (V1 vs V3 p = 0.0129) 
but not IFN-γ declined in the BCG naïve control females too 
(Figures 3A,B). BCG naïve females showed an increase in IFN-γ 
production to PMA/ionomycin by V3 (V1 to V3: p =  0.0019; 
and V2 to V3: p =  0.0334), while the BCG vaccinated females 
did not (Figure 3C). BCG naïve, but not vaccinated, males had 
increased IL-2 production to both the TLR2 ligand HKLM (V1 
vs V2 p = 0.0057) (Figure 3D) and CA (V1 vs V2 p = 0.0207) 
(Figure  3E) at V2, which declined by V3 (HKLM V2 vs V3 
p = 0.0005; CA V2 vs V3 p = 0.026). The BCG vaccinated males 
also had an increase in IL-2 to CA at V2, which did not quite 
reach significance (p = 0.0512), but declined significantly by V3 
(V2 vs V3 p = 0.0498) (Figure 3E). The only effect on intracellular 
cytokine production by flow cytometry after stimulating with the 
TLR ligands and heat-killed pathogens was an increase in IFN-γ 
from CD8+ T cells after CA stimulation in the BCG vaccinated 
females at V2 compared to V1 (p =  0.0316) (Figure  3F). The 
FigUre 2 | Sex-differential changes in purified protein derivative (PPD) reactivity. Figure shows comparisons of means within sexes for analyses with significant 
effects (main effect of interactions) involving bleed for the cytokine responses to stimulation with PPD. Significant effects were only observed in females and not male 
infants. The bacillus Calmette–Guérin (BCG) vaccinated females had detectable responses at baseline, in particular IFN-γ and IL-10, but these were not boosted 
further 1 (V2) or 12 weeks (V3) post-vaccination. Indeed, by V3, there was a significant decline in IL-12(p70) (a), IFN-γ (B), IL-4 (c), IL-10 (D), and IL-17  
(e) at V3 in the BCG vaccinated females. Mean baseline levels were low at baseline for the BCG naïve group, but increased significantly for IFN-γ (B), IL-4  
(c), and IL-17 (e) by V2 (+1 week). A fitted linear mixed model of cytokine values was used to determine significant differences by vaccine group, bleed, and sex. 
*p < 0.05, **p < 0.01, and ***p < 0.001. The figures show the arithmetic mean and SEM for cytokines in picograms per milliliter. Data shown for n = 93 infants 
(26 BCG vaccinated females, 18 BCG vaccinated males, 24 control females, and 25 control males).
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FigUre 3 | Th1 polarizing cytokine responses. The Th1 polarizing cytokines IL-12(p70), IL-2, and IFN-γ were measured in culture supernatants and IFN-γ was 
measured in CD4, CD8 T cells, and non-T cells by flow cytometry. Only significant effects by vaccine group, bleed, and sex using a fitted linear mixed model of 
cytokine values are shown. These indicated effects on IL-12(p70) (a) and IFN-γ (B) responses to LPS in females; IFN-γ responses to PMA in females  
(c); IL-2 responses to HKLM (D) and CA (e) in males; and intracellular staining (ICS) IFN-γ CD8+ T cell responses in to CA females (F) and males (g). *p < 0.05 and 
**p < 0.01. The figures show the arithmetic mean and SEM for cytokines in picograms per milliliter (a–e) or % positive cells of the gated CD8+ population (F,g).  
CA, Candida albicans; HKLM, heat-killed Listeria monocytogenes; LPS, lipopolysaccharide; PMA, phorbol myristate acetate/ionomycin. Data shown for n = 79 
infants [23 bacillus Calmette–Guérin (BCG) vaccinated females, 15 BCG vaccinated males, 21 control females and 20 control males].
FigUre 4 | Th1:Th2 cytokine balance. IFN-γ:IL-4 in LPS (a) and CLO-75 (B) culture supernatants declined by V3 (+12 weeks) in bacillus Calmette–Guérin (BCG) 
naïve, but not vaccinated, males. IFN-γ:IL-4 to SP declined at V2 (+1 week) in BCG vaccinated, but not naïve, females, then increased to baseline levels by V3 
(+12 weeks) (c). *p < 0.05. The figures show the geometric mean and 95% CI for cytokines in picograms per milliliter. LPS, lipopolysaccharide; SP, Streptococcus 
pneumoniae. Data shown for n = 79 infants (23 BCG vaccinated females, 15 BCG vaccinated males, 21 control females, and 20 control males).
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similar increase in CA-specific CD8+IFN-γ+ responses from V1 
to V2 was not significant in the males, but the level at V2 was 
significantly higher than at V3 (p = 0.0151) (Figure 3G).
While the Th2 cytokine IL-4 was not affected by vaccine group 
or sex in culture supernatants, the ratio of IFN-γ to IL-4, indicative 
of the Th1:Th2 cytokine balance, was affected. Thus, BCG naïve 
males had decreased IFN-γ:IL-4 at V3 to TLR4 (LPS) (V1 vs V3 
p = 0.039) (Figure 4A) and TLR7/8 (CLO-75) stimulation (V2 
vs V3 p = 0.0194) (Figure 4B); and BCG vaccinated females had 
decreased IFN-γ:IL-4 to SP at V2 compared to baseline (V1 vs V2 
p = 0.0128) which increased again by V3 (V2 vs V3 p = 0.0227) 
(Figure 4C; Table 3; Tables S2 and S3 in Supplementary Material).
sex-Differential effects on the  
anti-inflammatory cytokine il-10
IL-10 is an anti-inflammatory cytokine that can be produced by 
T helper 1 (Th1), Th2, and regulatory T cells (41). IL-10 responses 
FigUre 5 | Effects on the anti-inflammatory cytokine IL-10. The modeling analysis showed differences by vaccine group, bleed, and sex for female IL-10 responses 
to LPS (a) and CA (B). IFN-γ:IL-10 ratios declined in SP cultures in bacillus Calmette–Guérin (BCG) naïve females (c); and declined in SP (D), HKLM (e), and LPS 
(F) cultures in BCG naïve males. TNF-α:IL-10 levels decreased by V3 (+12 weeks) in EC (g) and SP (h) cultures in BCG naïve females. *p < 0.05, **p < 0.01, and 
***p < 0.001. The figures show the arithmetic mean and SEM for individual cytokines in picograms per milliliter, and geometric mean and 95% CI for log transformed 
cytokine ratios. CA, Candida albicans; EC, Escherichia coli; HKLM, heat-killed Listeria monocytogenes; LPS, lipopolysaccharide; SP, Streptococcus pneumoniae. 
Data shown for n = 79 infants (23 BCG vaccinated females, 15 BCG vaccinated males, 21 control females, and 20 control males).
TaBle 3 | Summary of all significant sex-by-bleed-by-group interactions for the whole blood culture and intracellular staining assays.
innate 
cytokines
Th1 cytokines Th2 
cytokines
Th1:Th2 ratio anti-
inflammatory
Pro- to 
anti-inflammatory
Th17 
cytokines
TnF-α il-12(p70), il-2, iFn-γ il-4 iFn-γ:il-4 il-10 iFn-γ:il-10, TnF:il-10 il-17
Visit 2 (+1 week)
Naïve females No effect No effect No effect No effect ↑ to CA ↓ to SP No effect
Bacillus Calmette–Guérin 
(BCG) females
No effect ↑ CD8+IFN-γ+ to CA No effect ↓ to SP No effect No effect No effect
Naïve males No effect ↑ to TLR2 and CA No effect No effect No effect No effect ↑ to TLR2
BCG males No effect ↑ CD8+IFN-γ+ to CA No effect No effect No effect No effect No effect
Visit 3 (+12 weeks)
Naïve females No effect ↓ to TLR4, ↑ to PMA No effect No effect ↑ to CA ↓ to SP, EC No effect
BCG females No effect ↓ to TLR4 No effect ↑ to SP ↓ to TLR4 No effect ↓ to TLR2
Naïve males No effect ↓ to TLR2 and CA No effect ↓ to TLR4  
and TLR7/8
No effect No effect No effect
BCG males No effect ↓ to CA No effect No effect No effect ↓ to SP, TLR2, TLR4 No effect
Table summarizing all significant interactions in the linear mixed model analysis showing that cytokine changes are sex, group, and time differential.
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to TLR4 (LPS) declined in the BCG vaccinated females by V3 
(V2 vs V3 p =  0.0482) (Figure  5A), while IL-10 responses to 
CA increased in the BCG naïve but not vaccinated females at 
V2 with a further increase at V3 (V1 vs V3 p = 0.0001, V2 vs 
V3 p = 0.0217) (Figure 5B; Tables S2 and S3 in Supplementary 
Material). There was no effect of vaccine group, bleeding time 
point, or sex on ICS IL-10 responses to any antigen (data not 
shown).
Bacillus Calmette–Guérin naïve females had a decrease 
in IFN-γ:IL-10 to SP at V2 and V3 (V1 vs V2 p =  0.0191; V1 
vs V3 p = 0.0141) (Figure 5C), and BCG naïve males likewise 
had a decline in IFN-γ:IL-10 to SP at V3 (V2 vs V3 p = 0.0472) 
(Figure 5D). BCG naïve males also had a decline in IFN-γ:IL-10 
to TLR2 (HKLM) (V2 vs V3 p = 0.017) (Figure 5E) and TLR4 
(LPS) in vitro at V3 (V1 vs V3 p = 0.0342; V2 vs V3 p = 0.0163) 
(Figure 5F). Furthermore, the ratio of TNF-α to IL-10 in EC (V1 
vs V3 p = 0.005; V2 vs V3 p = 0.0457) (Figure 5G) and SP cultures 
(V1 vs V3 p = 0.0028) (Figure 5H) decreased by V3 in the naïve 
females, but remained constant in those who received BCG. This 
effect was not observed in male infants (Table 3).
FigUre 6 | IL-17 responses. IL-17 responses in heat-killed Listeria monocytogenes (HKLM) cultures increased in bacillus Calmette–Guérin (BCG) naïve males at V2 
(+1 week) (a), and decreased in HKLM cultures in BCG vaccinated females (B). *p < 0.05 and **p < 0.01. The figures show the arithmetic mean and SEM for IL-17 
in picograms per milliliter. Data shown for n = 79 infants (23 BCG vaccinated females, 15 BCG vaccinated males, 21 control females, and 20 control males).
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sex-Differential effects of Bcg 
Vaccination on il-17 responses  
to Tlr2 ligand stimulation
IL-17 production following TLR2 ligand (HKLM) stimulation 
increased at V2 in the BCG naïve (V1 vs V2 p =  0.0407), but 
not vaccinated, males (Figure  6A); and HKLM-specific IL-17 
declined at V3 in BCG vaccinated (V1 vs V3 p = 0.0165), but not 
naïve, females (Figure 6B). There was no effect of vaccine group 
or sex on IL-17 responses for any of the other stimuli (Tables S2 
and S3 in Supplementary Material). IL-17 reactivity in CD4+, 
CD8+, or CD3− cells by ICS was not affected by BCG vaccination 
or sex at any time point (Table 3).
no effect of Bcg Vaccination at 6 Weeks 
on antibody responses to Other ePi 
Vaccines
Since BCG has been shown to boost antibody responses to other 
EPI vaccines, even when given before the vaccine in question (35), 
we measured antibody levels to hepatitis B vaccine, poliovirus 
serotypes 1 and 3, diphtheria toxoid, tetanus toxoid (TT), and 
pertussis toxoid. There was significant induction of antibody 
responses to all vaccines by V3, but not V2, compared to V1 
(Table  4). All infants except for one had protective antibody 
levels to TT at V1, confir ming a benefit of maternal vaccination, 
as expectant mothers in The Gambia receive two doses of TT vac-
cine during the second and third trimesters. No additional boost-
ing effect was observed in the BCG vaccinated group compared 
to the naïve group for any of the vaccines. The only sex difference 
was higher HepB IgG levels in control males compared to control 
females at V3 (p = 0.040), while no such difference was observed 
in the BCG vaccinated group.
DiscUssiOn
The lack of consistent and reliable protection by BCG has galva-
nized the search for new vaccination strategies using recombinant 
technology or heterologous vector-based vaccines (42, 43), as a 
prime-boost to neonatal BCG vaccination. To develop optimal 
vaccination strategies, it is important to understand the role that 
the heterologous effects of BCG vaccination play in TB endemic 
settings. The aim of this study was to analyze in vitro reactivity to 
innate ligands and a panel of common pathogens to see if BCG 
vaccination of 6-week-old Gambian infants enhanced reactivity 
to these antigens compared to BCG naïve infants.
One of the surprising findings in this study was a lack of induced 
in vitro reactivity to PPD in the BCG vaccinated infants. However, 
the BCG vaccinated group had good induction of TST reactivity 
compared to the naïve group suggesting that the vaccine was effec-
tive. In this study, we performed overnight cultures only, whereas 
we have previously shown that T cell responses to PPD generally 
peak at 5–7  days of culture (13), thus we probably measured 
predominantly innate responses to intrinsic PAMPs expressed by 
mycobacteria in the BCG vaccine (44), which were not boosted by 
vaccination. Indeed, paradoxically, the BCG vaccinated females 
had a decline in Th1, Th2, and IL-17 cytokine reactivity to PPD 
at V3, while the BCG naïve infants experienced an increase in 
reactivity. This decline may be due to the intervening vaccines 
given including DTwP that has specifically been shown to sup-
press innate and adaptive immunity in Gambian females but not 
males (45). One week is very early for detection of memory T cell 
responses following BCG vaccination, so this early time point 
also likely contributed to lack of induced PPD responses. It is also 
possible that the PPD itself was not immunogenic; however, the 
same batch was effective in previous studies. We used BCG Russia 
in this study which has been shown to have poor immunogenicity 
compared to other strains such as BCG Japan and BCG Denmark 
(6, 46, 47), which would further contribute to low PPD reactiv-
ity in our study. Another explanation is that the mycobacterial 
response may have been negatively attenuated by environmental 
bacteria, although our previous studies in infants from the same 
study area do not support this conclusion (13).
Previous studies have shown that BCG can “train” the innate 
immune system of healthy European adults via epigenetic 
TaBle 4 | Antibody titers to EPI vaccines in the bacillus Calmette–Guérin (BCG) vaccinated and naïve infants.
Vaccine 
type 
(unit)
Visit Bcg vaccinated group Bcg naïve control group
Males Boost 
from 
baseline
Females Boost 
from 
baseline
Males  
vs 
females
Males Boost 
from 
baseline
Females Boost 
from 
baseline
Males  
vs 
Females
Median (iQr) p-Value Median (iQr) p-Value p-Value Median (iQr) p-Value Median (iQr) p-Value p-Value
Polio 1 
(titers)
1 24 (8, 160) 32 (8, 112) NS 16 (8, 112) 16 (8, 48) NS
2 48 (16, 256) NS 48 (20, 512) NS NS 24 (16, 256) NS 32 (16, 64) NS NS
3 256 (32, 1,024) 0.0003 768 (128, 1,024) <0.0001 NS 256 (160, 512) <0.0001 192 (64, 1,024) <0.0001 NS
Polio 3 
(titers)
1 8 (8, 80) 8 (8, 14) NS (8, 8) 8 (8, 12) NS
2 24 (8, 128) NS 8 (8, 32) NS NS 8 (8, 40) NS 8 (8, 16) NS NS
3 256 (128, 512) 256 (56, 640) <0.0001 NS 256 (32, 1,024) <0.0001 256 (10, 512) <0.0001 NS
HepB  
(IU/mL)
1 10 (10, 10) 10 (10, 10) NS 10 (10, 10) 10 (10, 10) NS
2 10 (10, 10) NS 10 (10, 10) NS NS 10 (10, 10) NS 10 (10, 10) NS NS
3 483 (364, 1,000) <0.0001 650 (394, 1,000) <0.0001 NS 1,000 (393, 1,000) 353 (241, 1,000) <0.0001 0.04
Diphtheria 
toxoid  
(IU/mL)
1 0.01 (0.01, 0.02) 0.01 (0.01, 0.02) NS 0.01 (0.00, 0.03) 0.01 (0.00, 0.01) NS
3 2.6 (1.4, 3.7) <0.0001 2.7 (1.9, 4.1) <0.0001 NS 2.8 (1.7, 4.4) <0.0001 1.8 (1.2, 3.0) <0.0001 NS
Pertussis 
toxoid 
(EU/mL)
1 3.0 (1.5, 9.6) 5.0 (1.2, 9.5) NS 4.6 (1.8, 8.8) 4.1 (1.6, 9.7) NS
3 252 (112, 572) <0.0001 225 (123, 568) <0.0001 NS 240 (61, 582) <0.0001 268 (69, 523) <0.0001 NS
Tetanus 
toxoid (TT) 
(IU/mL)
1 1.7 (0.7, 3.2) 1.9 (0.8, 3.0) NS 1.3 (0.6, 3.2) 1.0 (0.4, 2.6) NS
3 7.5 (3.2, 10.5) <0.0001 5.5 (3.8, 15.6) 0.003 NS 6.3 (3.4, 17.8) <0.0001 6.7 (3.5, 8.1) <0.0001 NS
Summary of antibody levels at each visit for polio 1 and 3, hepatitis B, diphtheria toxoid, pertussis toxoid, and TT showing significant boosting of levels in both vaccine groups by 
visit 3 (+12 weeks). BCG naïve males had higher HepB antibody titers at visit 3 compared to BCG naïve females; this was not the case for the BCG vaccinated males and females.  
A fitted linear mixed model of log transformed antibody values was used to determine significant differences by vaccine group, bleed and sex. Data shown for n = 126 infants  
(30 BCG vaccinated females, 33 BCG vaccinated males, 28 control females, and 35 control males).
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modification of innate immune cells leading to enhanced pro-
inflammatory responses to a range of stimuli (27, 48–51). 
Furthermore, we have previously found that neonatal BCG 
vaccination enhanced reactivity to certain TLR ligands in a 
sex-differential manner, with greater enhancement in females 
than males (49). However, in this study, we found no evidence 
of enhanced innate responses (analyzed by TNF-α production) 
in BCG vaccinated infants in culture supernatants or by ICS. 
The reason for the discrepancy with previous studies could be 
due to a number of factors including differences in experimental 
techniques, the age group at which BCG was given, key genetic 
differences, and exposure to environmental mycobacteria. 
Another likely contributory factor is our use of BCG Russia since 
the previous immune-enhancing studies used BCG Denmark. 
BCG scar rates predict non-specific beneficial effects, and those 
immunized with BCG Russia have lower scar rates (approximately 
50%) compared to BCG Denmark (72–97%) (6). By implication, 
this would suggest that BCG Russia is less likely to have beneficial 
non-specific effects that BCG Denmark (5). This was confirmed 
in a study conducted in more than 1,000 infants in Uganda in 
which BCG Denmark was found to have stronger non-specific 
immunological effects than BCG Russia and BCG Bulgaria (4). 
Ongoing studies are hoping to confirm this critical issue.
The Th1 polarizing cytokines IL-2, IL-12(p70), and IFN-γ 
were all affected by vaccine group and sex in this study. The 
increased CD8+ T cell IFN-γ production to C. albicans in males 
and females 1 week after BCG vaccination supports early immune 
enhancement by the vaccine. There were no other enhanced Th1 
type cytokine responses in BCG vaccinated males or females. 
On the contrary, BCG vaccinated females had decreased 
IFN-γ:IL-4 to SP 1 week after vaccination.
Many of the significant changes in cytokine reactivity occurred 
at V3 (+12 weeks) rather than V2 (+1 week). For example, at V3, 
both BCG vaccinated and naïve infants had decreased Th1 cytokine 
reactivity and decreased pro- to anti-inflammatory cytokine ratios 
to certain stimuli. Between V2 and V3 all infants received three 
doses of OPV, pentavalent vaccine (diphtheria, tetanus, whole 
cell pertussis, Haemophilus influenzae type b, hepatitis B), and 
PCV-13 at 8, 12, and 16 weeks of age, all of which are likely to have 
heterologous effects on innate and adaptive immunity. Indeed, 
we have shown that DTwP vaccination leads to decreased innate 
and T  cell responses in infant females but not males (45), and 
OPV has also been shown to attenuate immune responses to BCG 
vaccination (49). Thus, changes in immune reactivity observed in 
this study may also reflect heterologous effects of these vaccines, 
and differences between the BCG vaccinated and naïve groups 
are likely reflect the additional immune modifying effects of 
BCG. In particular, the negative heterologous effects of DTwP 
(45) could explain the decline in PPD reactivity for multiple 
cytokines in BCG vaccinated females but not males at V3.
IL-10 is a key anti-inflammatory cytokine, implicated in the 
homeostatic regulation of inflammatory responses (41). TLR4-
specific IL-10 responses declined in BCG vaccinated females, and 
IL-10 reactivity to C. albicans increased in BCG naïve females at 
both V2 and V3. BCG naïve males and females also had decreased 
IFN-γ:IL-10 and TNF-α:IL-10 ratios to a range of stimuli. These 
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results suggest a skewing of immunity toward a more anti-
inflammatory profile in those infants who had not received BCG, 
which was prevented by the prior administration of BCG. Greater 
anti-inflammatory responses may be detrimental by resulting in 
less efficient pathogen clearance, and prevention of it by prior 
administration of BCG could provide an immunological benefit.
Th17 cells have been implicated in protective mycobacterial 
responses after BCG vaccination (16, 52) and in clearing a range 
of other pathogens (53). However, we observed high levels of 
IL-17 production from non-T cells after stimulation with PPD, 
and thus not a Th17 response; and further found no difference 
between BCG vaccinated and naïve infants following stimulation 
with antigens (both vaccine-specific and unrelated) suggesting 
no effect of BCG vaccination. However, BCG naïve males had 
evidence of increased IL-17 reactivity to TLR2, while BCG 
vaccinated females had a decrease, supporting sex-differential 
enhanced IL-17 immunity in the naïve group.
In summary, we found no evidence that BCG vaccination of 
6-week-old Gambian infants alters innate immunity and have 
shown that Th1 and IL-17 cytokine responses were more likely 
to increase over time in the BCG naïve individuals. However, the 
BCG naïve group also had decreased pro- to anti-inflammatory 
cytokine ratios (IFN-γ:IL-4, IFN-γ:IL-10, and TNF-α:IL-10) and 
increased IL-10 to certain stimuli, indicating a bias toward an 
anti-inflammatory response. All of these effects were sex differ-
ential, with males and females often showing opposite patterns. 
This is in keeping with the growing body of literature reporting 
sex differences in immunity (54). These sex differences are likely 
caused by a combination of factors including differences in sex 
hormone levels and expression of X-linked immune response 
genes. Estrogens are generally immune enhancing and higher in 
females most of the first year of life; and males undergo a tes-
tosterone surge at about 6 weeks of age, which is known to have 
immunosuppressive effects on immunity (55).
It has been shown that concomitant administration of BCG 
can enhance antibody responses to other EPI vaccines, including 
hepatitis B, TT, and OPV (15). Furthermore, certain pneumococ-
cal vaccine serotypes were boosted in infants immunized with 
BCG at birth indicating that BCG can affect responses to vaccines 
given later in infancy (35). We did not find a boosting effect of 
BCG vaccine on the any of the vaccine antibody levels measured. 
This might be due to the different vaccine strain used in our 
study as discussed earlier; or the timing of BCG vaccination at 
6 weeks of age and thus 6 weeks after their birth HBV and OPV, 
and 2 weeks before their first pentavalent vaccine (DTP, Hib, and 
HBV). Importantly, however, protective antibody levels to polio, 
TT, and hepatitis B were achieved in all subjects regardless of 
vaccine group, showing that the delay in BCG vaccination was 
not detrimental to antibody levels in our study. Control males had 
higher hepatitis B titers than females, which contradicts previous 
studies showing higher responses among females (54).
Several limitations to this study should be borne in mind. 
First, the vaccine was administered at 6 weeks of age rather than 
at birth, yet it is recommended that the vaccine be given at the 
earliest opportunity after birth. However, in the real life setting, 
it is estimated that less than half receive BCG in the first month 
of life, often because BCG comes in multi-dose vials that are not 
opened until there are sufficient infants to vaccinate (6). Another 
limitation is the infant numbers assessed since we had limited 
PBMCs available from study children due to a technical problem 
with the fresh blood assay. We only cultured overnight which is 
not optimal for measuring T cell responses since our study was 
not focused on innate immune stimulation.
In conclusion, BCG Russia given to African infants at 6 weeks 
of age had no effect on antibody responses to EPI vaccines, or on 
innate or Th2 cytokine responses to TLR or pathogen stimulation. 
There was early upregulation of C. albicans-specific CD8+IFN-γ+ 
responses in BCG vaccinated infants, but a decline in SP reactiv-
ity in BCG vaccinated females. By 18 weeks of age, Th1 cytokine 
responses were downmodulated in BCG vaccinated and naïve 
infants; TLR-stimulated IL-10 and IL-17 responses declined in 
BCG vaccinated females; and IL-10 production increased in BCG 
naïve females. The changes at 18 weeks are likely attributable to 
immunomodulatory effects of the EPI vaccines given at 8, 12, and 
16 weeks of age. However, the more anti-inflammatory immune 
profile in BCG naïve infants also suggests that prior BCG vac-
cination may prevent this immune skewing. The results suggest 
that BCG Russia does not enhance innate immunity in the same 
way as BCG Denmark, but has a short-lived immune-enhancing 
effect on CD8+ T cell reactivity to C. albicans only and possibly 
deviates the immune system away from an anti-inflammatory 
IL-10 response. This is the first study to analyze for heterologous 
effects of BCG Russia, which is important since it is the most 
widely administered BCG strain worldwide at this time (6).
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FigUre s1 | Gating strategy for CD4 and CD8 T cells by flow cytometry. 
Lymphocytes were gated on a forward and side scatter plot (a), then singlets 
(B) followed by viable cells by gating out live-dead positive cells (c). Viable 
lymphocytes were separated into CD3+ followed by the CD4+ and CD8+ 
populations (D), and the CD3 negative population was identified on a 
histogram (e).
FigUre s2 | Gating strategy for intracellular staining by flow cytometry. 
Representative plots showing the intracellular cytokine production following 
PMA/ionomycin stimulation for CD3−, CD4+, and CD8+ T cells. Boolean gating 
was used to quantify cytokine positive cells for the five intracellular cytokines— 
IL-2, IFN-γ, TNF-α, IL-10, and IL-17.
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